Qinjie Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Qinjie Wu has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
- Changyang Gong
Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China
27 shared publications Meiling Shen
Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, P. R. China
11 shared publicationsTao He
Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, P. R. China
9 shared publicationsXinchao Li
Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China
9 shared publicationsJin Yang
Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital
7 shared publicationsNing Wang
Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China
7 shared publications
Latest Publications
- 11 November 2026
- Published by Springer Nature in Nature Biomedical Engineering
- p. 1
Author Correction: A HO-1 gene knockout using a NanoCRISPR scaffold suppresses metastasis in mouse models
- 11 November 2026
- Published by Springer Nature in Nature Biomedical Engineering
- p. 1
Author Correction: A HO-1 gene knockout using a NanoCRISPR scaffold suppresses metastasis in mouse models
- 6 October 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20  (41) , 27559-27640
Nano Delivery Systems for In Vivo CRISPR/Cas-Based Gene Therapy: From Vectors to Clinical Outcomes
As a powerful gene-editing tool, the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) system features simple construction, precise targeting, and higher editing efficiency, bringing prospects of radical cures for numerous critical illnesses at the genomic level. To date, ex vivo CRISPR/Cas-based gene therapies represented by Casgevy have achieved significant clinical advances. Nevertheless, cumbersome operational workflows and prohibitive treatment costs severely hinder their widespread clinical accessibility. In contrast, in vivo CRISPR/Cas-based gene therapies stand out with convenient administration procedures and reduced overall costs, endowing them with enormous translational potential. Although it holds great promise, the clinical translation of in vivo CRISPR/Cas-based gene therapies remains hampered by a number of factors. Among those multiple obstacles restricting the clinical translation of in vivo CRISPR/Cas-based gene therapies, delivery systems constitute the core bottleneck dominating in vivo editing efficiency and therapeutic potency. Centered on delivery platforms for in vivo CRISPR/Cas-based gene therapies, this review systematically summarizes prevailing in vivo CRISPR/Cas nano delivery systems, recapitulates relevant preclinical and clinical outcomes, discusses translational hurdles, and prospects the evolution of next-generation delivery systems, aiming to facilitate further development of in vivo CRISPR/Cas-based gene therapies.
- 6 October 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20  (41) , 27559-27640
Nano Delivery Systems for In Vivo CRISPR/Cas-Based Gene Therapy: From Vectors to Clinical Outcomes
As a powerful gene-editing tool, the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) system features simple construction, precise targeting, and higher editing efficiency, bringing prospects of radical cures for numerous critical illnesses at the genomic level. To date, ex vivo CRISPR/Cas-based gene therapies represented by Casgevy have achieved significant clinical advances. Nevertheless, cumbersome operational workflows and prohibitive treatment costs severely hinder their widespread clinical accessibility. In contrast, in vivo CRISPR/Cas-based gene therapies stand out with convenient administration procedures and reduced overall costs, endowing them with enormous translational potential. Although it holds great promise, the clinical translation of in vivo CRISPR/Cas-based gene therapies remains hampered by a number of factors. Among those multiple obstacles restricting the clinical translation of in vivo CRISPR/Cas-based gene therapies, delivery systems constitute the core bottleneck dominating in vivo editing efficiency and therapeutic potency. Centered on delivery platforms for in vivo CRISPR/Cas-based gene therapies, this review systematically summarizes prevailing in vivo CRISPR/Cas nano delivery systems, recapitulates relevant preclinical and clinical outcomes, discusses translational hurdles, and prospects the evolution of next-generation delivery systems, aiming to facilitate further development of in vivo CRISPR/Cas-based gene therapies.
- 14 May 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20  (20) , 14443-14457
Multistage Responsive NanoCRISPR Unleashes Cascade Amplified Endogenous Apoptosis and Inhibits Epithelial-Mesenchymal Transition Simultaneously for Suppressing Tumor Growth and Metastasis
Targeting apoptotic pathways holds promise for cancer treatment; however, single-pathway approaches often struggle to overcome apoptosis resistance and metastasis. Overexpression of Inhibitor of Apoptosis Proteins (IAPs), particularly Survivin, is critically linked to these therapeutic challenges. Herein, a multistage-responsive nanoCRISPR (MIRV) system targeting the IAPs member Survivin in the nucleus and mitochondria in the cytoplasm was developed to suppress tumor growth and metastasis via cascade-amplified endogenous apoptosis and epithelial-mesenchymal transition (EMT) inhibition. By leveraging the tumor-specific targeting, enzyme-triggered penetrating and deshelling, and reactive oxygen species (ROS)-responsive capabilities, MIRV precisely delivers the Survivin-targeting CRISPR/Cas9 system and the pro-apoptotic peptide D(KLAKLAK)2 to the nucleus and cytoplasm of tumor cells, respectively. Survivin depletion-triggered endogenous apoptosis and EMT inhibition, cooperating with peptide-induced mitochondrial dysfunction, enabled MIRV to markedly suppress subcutaneous tumor growth and peritoneal metastasis with minimal side effects. Taken together, the MIRV system provides an effective strategy for the simultaneous induction of apoptosis and suppression of EMT in antitumor and antimetastatic therapies.
- 14 May 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20  (20) , 14443-14457
Multistage Responsive NanoCRISPR Unleashes Cascade Amplified Endogenous Apoptosis and Inhibits Epithelial-Mesenchymal Transition Simultaneously for Suppressing Tumor Growth and Metastasis
Targeting apoptotic pathways holds promise for cancer treatment; however, single-pathway approaches often struggle to overcome apoptosis resistance and metastasis. Overexpression of Inhibitor of Apoptosis Proteins (IAPs), particularly Survivin, is critically linked to these therapeutic challenges. Herein, a multistage-responsive nanoCRISPR (MIRV) system targeting the IAPs member Survivin in the nucleus and mitochondria in the cytoplasm was developed to suppress tumor growth and metastasis via cascade-amplified endogenous apoptosis and epithelial-mesenchymal transition (EMT) inhibition. By leveraging the tumor-specific targeting, enzyme-triggered penetrating and deshelling, and reactive oxygen species (ROS)-responsive capabilities, MIRV precisely delivers the Survivin-targeting CRISPR/Cas9 system and the pro-apoptotic peptide D(KLAKLAK)2 to the nucleus and cytoplasm of tumor cells, respectively. Survivin depletion-triggered endogenous apoptosis and EMT inhibition, cooperating with peptide-induced mitochondrial dysfunction, enabled MIRV to markedly suppress subcutaneous tumor growth and peritoneal metastasis with minimal side effects. Taken together, the MIRV system provides an effective strategy for the simultaneous induction of apoptosis and suppression of EMT in antitumor and antimetastatic therapies.
- Open Access
- 31 March 2026
- Published by Elsevier in Cell Reports Medicine
- Vol. 7  (4) , 102718
A harmless-to-harmful switchable and spatiotemporally activated nano-CRISPR hierarchically amplifies ferroptosis in melanoma
- 31 March 2026
- Published by Elsevier in Cell Reports Medicine
- Vol. 7  (4) , 102718
Open AccessA harmless-to-harmful switchable and spatiotemporally activated nano-CRISPR hierarchically amplifies ferroptosis in melanoma
- Open Access
- 2 February 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24  (1)
Tumor-activated dual metabolic nanomodulator turns over tolerogenic tumor control and unleashes systemic immune responses
Temporary amelioration of immunosuppression following extrinsic stress-induced immunogenic signal release provides opportunities for immunotherapy improvem
- 2 February 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24  (1)
Open AccessTumor-activated dual metabolic nanomodulator turns over tolerogenic tumor control and unleashes systemic immune responses
Temporary amelioration of immunosuppression following extrinsic stress-induced immunogenic signal release provides opportunities for immunotherapy improvem
- Open Access
- 1 January 2026
- Published by Ivyspring International Publisher in Theranostics
- Vol. 16  (3) , 1432-1444
Limitation-circumventing and strength-capitalizing hydrogel potentiates durable antitumor immunity and robust abscopal effect in radiotherapy
Background: Radiotherapy (RT)-induced antitumor immunity has attracted extensive attention. However, such antitumor immunity often proves inadequate to combat metastatic and recurrent tumors in clinical practice. While hypoxia severely limits the initiation of adequate systemic antitumor immune responses, the strength of such responses is further compromised by the blockage of effector T cells, ultimately undermining the ability of RT to elicit a robust abscopal effect and durable immune memory.
- 1 January 2026
- Published by Ivyspring International Publisher in Theranostics
- Vol. 16  (3) , 1432-1444
Open AccessLimitation-circumventing and strength-capitalizing hydrogel potentiates durable antitumor immunity and robust abscopal effect in radiotherapy
Background: Radiotherapy (RT)-induced antitumor immunity has attracted extensive attention. However, such antitumor immunity often proves inadequate to combat metastatic and recurrent tumors in clinical practice. While hypoxia severely limits the initiation of adequate systemic antitumor immune responses, the strength of such responses is further compromised by the blockage of effector T cells, ultimately undermining the ability of RT to elicit a robust abscopal effect and durable immune memory.
- 22 October 2025
- Published by Springer Nature in Nature Biomedical Engineering
- Vol. 10  (6) , 1096-1112
A HO-1 gene knockout using a NanoCRISPR scaffold suppresses metastasis in mouse models
Photodynamic therapy-induced immunogenic cell death has the potential to generate autologous cancer vaccines. However, the innate or evolved genetic tolerance of tumours limits the efficacy of this approach. Here we report the development of a heritable nanoplatform based on gene editing of haem oxygenase-1 (HO-1) using a NanoCRISPR/HO-1 scaffold. This platform effectively eliminates genetic tolerance to reactive oxygen species in tumours without causing adverse effects on main immune cells, resulting in a robust and durable immune response to autologous vaccine. This NanoCRISPR scaffold can inherit susceptibility to tumour progeny, transforming heterogeneous malignancies into a reactive oxyen species-sensitive phenotype. Moreover, the arginine-grafted polyethyleneimine module and CpG motif within the NanoCRISPR scaffold enhance the cancer-immune cycle by amplifying antigen generation, promoting T cell proliferation and activating adaptive immune response in cancer models. When combined with an αPD-L1 antibody, the NanoCRISPR scaffold-based heritable nanoplatform elicits antitumour immunity and durable immunological memory in vivo melanoma mouse models. This combinational therapy evokes a strong immune memory against tumour rechallenge, providing insights into the rational development of a cancer vaccine regimen.
- 22 October 2025
- Published by Springer Nature in Nature Biomedical Engineering
- Vol. 10  (6) , 1096-1112
A HO-1 gene knockout using a NanoCRISPR scaffold suppresses metastasis in mouse models
Photodynamic therapy-induced immunogenic cell death has the potential to generate autologous cancer vaccines. However, the innate or evolved genetic tolerance of tumours limits the efficacy of this approach. Here we report the development of a heritable nanoplatform based on gene editing of haem oxygenase-1 (HO-1) using a NanoCRISPR/HO-1 scaffold. This platform effectively eliminates genetic tolerance to reactive oxygen species in tumours without causing adverse effects on main immune cells, resulting in a robust and durable immune response to autologous vaccine. This NanoCRISPR scaffold can inherit susceptibility to tumour progeny, transforming heterogeneous malignancies into a reactive oxyen species-sensitive phenotype. Moreover, the arginine-grafted polyethyleneimine module and CpG motif within the NanoCRISPR scaffold enhance the cancer-immune cycle by amplifying antigen generation, promoting T cell proliferation and activating adaptive immune response in cancer models. When combined with an αPD-L1 antibody, the NanoCRISPR scaffold-based heritable nanoplatform elicits antitumour immunity and durable immunological memory in vivo melanoma mouse models. This combinational therapy evokes a strong immune memory against tumour rechallenge, providing insights into the rational development of a cancer vaccine regimen.
- Open Access
- 15 July 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122  (29)
A versatile immunomodulated nanoCRISPR converter augments the susceptibility and visibility of tumors to the immune system
Immune checkpoint blockade (ICB) has potential in alleviating cytotoxic T lymphocyte (CTL) exhaustion. However, resistance that impaired major histocompatibility complex class I (MHC-I) expression on tumors can be developed in many patients after ICB treatment, resulting in insufficient antigen presentation to CTLs. Herein, we rationally design a ver s atile and po w erful i mmunomodula t ed hierar ch ical nanoCRISPR converter (SWITCH) targeting PD-L1 and PCSK9 loci to convert the immune-resistance state of tumors with high PD-L1 and low MHC-I expression for augmenting the susceptibility and visibility of tumors to the immune system. SWITCH possesses enhanced blood circulation and tumor-targeting capacity through PEGylation, acid-triggered pH low insertion peptides (pHLIPs), and interaction of hyaluronan with CD44 receptors. With the assistance of hyaluronidase and preternatural oxidative stress within tumor cells, SWITCH undergoes enzyme-responsive disassembly, charge reversal, rapid lysosomal escape, and efficient disruption of PD-L1 and PCSK9 orderly. This dual-action mechanism simultaneously blocks PD-1/PD-L1 immunosuppression while restoring MHC-I-mediated antigen presentation, resulting in enhanced the susceptibility and visibility of tumors to the immune system. Our results demonstrate SWITCH's remarkable efficacy in suppressing primary, contralateral, and recurrent tumor growth. Taken together, our study provides an encouraging strategy for relieving tumor immune resistance and further potentiating the efficacy of ICB.
- 15 July 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122  (29)
Open AccessA versatile immunomodulated nanoCRISPR converter augments the susceptibility and visibility of tumors to the immune system
Immune checkpoint blockade (ICB) has potential in alleviating cytotoxic T lymphocyte (CTL) exhaustion. However, resistance that impaired major histocompatibility complex class I (MHC-I) expression on tumors can be developed in many patients after ICB treatment, resulting in insufficient antigen presentation to CTLs. Herein, we rationally design a ver s atile and po w erful i mmunomodula t ed hierar ch ical nanoCRISPR converter (SWITCH) targeting PD-L1 and PCSK9 loci to convert the immune-resistance state of tumors with high PD-L1 and low MHC-I expression for augmenting the susceptibility and visibility of tumors to the immune system. SWITCH possesses enhanced blood circulation and tumor-targeting capacity through PEGylation, acid-triggered pH low insertion peptides (pHLIPs), and interaction of hyaluronan with CD44 receptors. With the assistance of hyaluronidase and preternatural oxidative stress within tumor cells, SWITCH undergoes enzyme-responsive disassembly, charge reversal, rapid lysosomal escape, and efficient disruption of PD-L1 and PCSK9 orderly. This dual-action mechanism simultaneously blocks PD-1/PD-L1 immunosuppression while restoring MHC-I-mediated antigen presentation, resulting in enhanced the susceptibility and visibility of tumors to the immune system. Our results demonstrate SWITCH's remarkable efficacy in suppressing primary, contralateral, and recurrent tumor growth. Taken together, our study provides an encouraging strategy for relieving tumor immune resistance and further potentiating the efficacy of ICB.
- 2 July 2025
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 19  (27) , 25552-25565
An Asynchronous-Regulated Nanosheet Cascade Amplifies Sonodynamic-Triggered Self-Enhanced DNA Damage for Intensive Tumor Immunotherapy
DNA damage can potentially trigger innate immune responses, providing a feasible way for immunotherapies to target "cold" tumors (T cell-deprived). However, DNA damage resistance and immunosuppression severely compromise tumor therapeutic efficacy. We therefore developed an ultrasound-activated and asynchronous-regulated nanosheet (ECHO). This system achieved cascade amplification of self-enhanced DNA damage via sonodynamic therapy, enabling potent tumor immunotherapy. Upon ultrasound activation, the peroxidase-like property conferred ECHO with the capability to induce precise and potent DNA damage by triggering ROS explosions, while leveraging the Russell mechanism to continuously generate ROS within the tumor microenvironment, heightening cellular susceptibility to DNA damage. Then, STING was activated and enhanced by DNA fragments and Mn2+ released from ECHO, respectively, which in turn disrupted ROS clearance for reversing tumor resistance to DNA damage and boosting innate immunity. Simultaneously, Niclosamide inhibited STAT3 in DNA repair response and counteracted immunosuppressive effects. The asynchronous regulation of STING and STAT3 increased ROS absolute content and restrained DNA repairing, facilitating self-enhanced DNA damage, thus intensifying tumor immunotherapy. ECHO effectively targeted tumors with minimal adverse effects, leading to 87% tumor regression and 40% contralateral bilateral tumor elimination. Overall, our asynchronous regulation strategy achieved self-enhancing DNA damage and offered a promising prototype for intensive tumor immunotherapy.
- 2 July 2025
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 19  (27) , 25552-25565
An Asynchronous-Regulated Nanosheet Cascade Amplifies Sonodynamic-Triggered Self-Enhanced DNA Damage for Intensive Tumor Immunotherapy
DNA damage can potentially trigger innate immune responses, providing a feasible way for immunotherapies to target "cold" tumors (T cell-deprived). However, DNA damage resistance and immunosuppression severely compromise tumor therapeutic efficacy. We therefore developed an ultrasound-activated and asynchronous-regulated nanosheet (ECHO). This system achieved cascade amplification of self-enhanced DNA damage via sonodynamic therapy, enabling potent tumor immunotherapy. Upon ultrasound activation, the peroxidase-like property conferred ECHO with the capability to induce precise and potent DNA damage by triggering ROS explosions, while leveraging the Russell mechanism to continuously generate ROS within the tumor microenvironment, heightening cellular susceptibility to DNA damage. Then, STING was activated and enhanced by DNA fragments and Mn2+ released from ECHO, respectively, which in turn disrupted ROS clearance for reversing tumor resistance to DNA damage and boosting innate immunity. Simultaneously, Niclosamide inhibited STAT3 in DNA repair response and counteracted immunosuppressive effects. The asynchronous regulation of STING and STAT3 increased ROS absolute content and restrained DNA repairing, facilitating self-enhanced DNA damage, thus intensifying tumor immunotherapy. ECHO effectively targeted tumors with minimal adverse effects, leading to 87% tumor regression and 40% contralateral bilateral tumor elimination. Overall, our asynchronous regulation strategy achieved self-enhancing DNA damage and offered a promising prototype for intensive tumor immunotherapy.